Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome

Gut

Volumn 64, Issue 9, 2015, Pages 1498-1500

  Cauchy, François ^a,b   Mebarki, Mouniya ^a   Albuquerque, Miguel ^c   Laouirem, Samira ^a   Rautou, Pierre Emmanuel ^b   Soubrane, Olivier ^b   Raymond, Eric ^b   Bedossa, Pierre ^a,c   Paradis, Valérie ^a,c  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b BEAUJON HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE; METFORMIN;

EID: 84941333829     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310069     Document Type: Article

References (10)

1. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies. Gut 2013;62:606-15.
2. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United states: A study in the SEER-Medicare database. Hepatology 2011;54: 463-71.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32.
4. Singh S, Singh PP, Singh AG, et al. Antidiabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol 2013;108:881-91.
5. Miyoshi H, Kato K, Iwama H, et al. Effect of the antidiabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2014;45:322-32.
6. Dallaglio K, Bruno A, Cantelmo AR, et al. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis 2014;35: 1055-66.
7. Tadakawa M, Takeda T, Li B, et al. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. Mol Cell Endocrinol 2015;399:1-8.
8. Qu H, Yang X. Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. Cell Biochem Biophys 2015;71:931-6.
9. Giannelli G, Rani B, Dituri F, et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: The role of the microenvironment. Gut 2014;63:1668-76.
10. Singh S, Singh PP. Metformin and risk of hepatocellular carcinoma: Are statins the missing link? Gut 2013;62:951-2.